PHOENIX — Recombinant human parathyroid hormone (PTH) given subcutaneously improved mineral homeostasis and was well tolerated in a 24-week phase 3 clinical trial of 134 adult patients with ...
NICE is unable to make a recommendation about the use in the NHS of recombinant human parathyroid hormone for treating hypoparathyroidism because Shire Pharmaceuticals (now part of Takeda) did not ...
The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results